Endocare
This article was originally published in The Gray Sheet
Executive Summary
Temperature-based targeted cryosurgery product used in four-year study shows an 85% success rate in treating confined prostate cancer in 586 patients. Over 500 subjects remained "cancer-free" following the temperature monitored "freezing" of cancerous tissue, Fred Lee, MD, Crittendon Hospital, Rochester, New York, says in a Aug. 4 Endocare release. He notes that prostate specific antigen rates for patients receiving the minimally invasive treatment were "virtually undetectable" (0.18 ng/ml) and that 98% of treated patients required only an overnight stay following treatment